首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1570944

C反應蛋白檢測市場、機會、成長動力、產業趨勢分析與預測，2024-2032

C-reactive Protein Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月09日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球C反應蛋白檢測市場價值約為32億美元，預計到2032年將達到約44億美元，2024-2032年複合年成長率為3.9%。這種成長是由慢性疾病患病率上升以及對 CRP 檢測的需求不斷增加所推動的，CRP 檢測對於診斷和管理這些疾病至關重要。類風濕性關節炎、心血管疾病和糖尿病等慢性疾病需要透過 CRP 檢測進行持續監測和管理。這些慢性病的增加加劇了對 CRP 檢測的早期發現和持續管理的依賴。世界衛生組織 (WHO) 2023 年報告稱，慢性病佔全球死亡人數的 71%，凸顯了對有效診斷和監測工具的迫切需求。因此，慢性病的激增正在推動全球對 CRP 檢測的需求。

整個C反應蛋白檢測產業根據檢測範圍、產品、檢測類型、應用和地區進行分類。

依產品細分，C反應蛋白檢測市場包括儀器、試劑盒和試劑。 2023年，試劑盒和試劑領域引領市場，營收達20億美元。試劑盒和試劑用途廣泛，並與各種儀器和平台相容。這種適應性適合多種 CRP 檢測，包括酵素連結免疫吸附檢測、免疫比濁檢測和化學發光免疫檢測，增強了它們在多種臨床環境中的吸引力。許多 CRP 測試套件優先考慮使用者友善性和快速結果。這些功能在及時決策至關重要的臨床環境中至關重要，使得這些試劑盒比複雜、耗時的方法更具吸引力。

C反應蛋白檢測市場的檢測類型包括化學發光免疫分析（CLIA）、酵素連結免疫吸附分析（ELISA）、免疫比濁分析等。免疫比濁分析領域預計將在預測期內以 16 億美元的收入引領市場。免疫比濁分析因其經濟實惠而脫穎而出，特別是與 CLIA 和 ELISA 等價格較高的選擇相比。這種成本優勢吸引了廣泛的醫療保健提供者，特別是小型診所和預算有限的實驗室。這些檢測因其快速處理和效率而聞名。

2023 年，北美 C 反應蛋白檢測市場規模達 12 億美元，並預計在未來幾年大幅成長。該地區正在努力解決慢性病高發生率的問題，特別是心血管疾病和糖尿病。這種上升推動了對 CRP 檢測的需求，因為監測 CRP 水平對於評估這些情況下的發炎很常見。北美先進的醫療基礎設施和廣泛的診斷技術進一步推動了 CRP 檢測市場的發展。該地區採用創新診斷工具並積極主動地進行早期疾病檢測，擴大了 CRP 檢測的使用。

產業生態系統分析
產業影響力
- 成長動力
  - 發炎性疾病等慢性疾病的盛行率不斷增加
  - 用於診斷和管理慢性病的 CRP 檢測需求激增
  - 技術進步
  - 對直接到家測試服務的需求不斷成長
- 產業陷阱與挑戰
  - 缺乏標準化
成長潛力分析
監管環境
技術景觀
報銷場景
波特的分析
PESTEL分析
未來市場趨勢
差距分析

第 4 章：競爭格局

介紹
公司股份分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
儀器儀表
試劑盒和試劑

第 6 章：市場估計與預測：按分析類型，2021 - 2032 年

主要趨勢
化學發光免疫分析 (CLIA)
酵素連結免疫吸附測定法 (ELISA)
免疫比濁法
其他檢測類型

第 7 章：市場估計與預測：按檢測範圍，2021 - 2032 年

主要趨勢
高敏感度 CRP (hs-CRP)
標準CRP

第 8 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
心血管疾病
傳染病
慢性發炎性疾病
其他應用

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

主要趨勢
醫院和診所
診斷實驗室
其他最終用戶

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Abbott
Agilent technologies
Aidian
Boditech Med, Inc.
Creative diagnostics
CTK Biotech
Danaher
DxGen Corp
F. Hoffmann-La Roche Ltd.
Getein Biotech, Inc.
Goldsite diagnostics
HORIBA, Ltd
Laboratory Corporation of American Holding
LumiraDX
Merck KGaA
Optibio co., Ltd
Randox Laboratories Ltd.
Siemens Healthineers AG

簡介目錄

Product Code: 10749

The Global C-reactive Protein Testing Market was valued at approximately USD 3.2 billion in 2023 and is projected to reach around USD 4.4 billion by 2032, reflecting a CAGR of 3.9% from 2024-2032. This growth is driven by the rising prevalence of chronic disorders and an increasing demand for CRP testing, crucial for diagnosing and managing these conditions. Chronic ailments like rheumatoid arthritis, cardiovascular diseases, and diabetes require consistent monitoring and management, facilitated by CRP testing. The uptick in these chronic conditions has intensified the reliance on CRP tests for early detection and ongoing management. The World Health Organization (WHO) reported in 2023 that chronic diseases accounted for 71% of global deaths, highlighting the urgent need for effective diagnostic and monitoring tools. Consequently, this surge in chronic diseases is propelling the global demand for CRP testing.

The overall C-reactive protein testing industry is classified based on the detection range, product, assay type, application, and region.

Segmented by product, the C-reactive protein testing market includes instruments, kits, and reagents. In 2023, the kits and reagents segment led the market, generating revenues of USD 2 billion. Kits and reagents are versatile and compatible with various instruments and platforms. This adaptability caters to diverse CRP assays, including enzyme-linked immunosorbent assay, immunoturbidimetric assay, and chemiluminescence immunoassay, enhancing their appeal across multiple clinical environments. Many CRP testing kits prioritize user-friendliness and rapid results. Such features are vital in clinical settings where timely decisions are paramount, making these kits more appealing than intricate, time-consuming methods.

Assay types in the C-reactive protein testing market include chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and others. The immunoturbidimetric assay segment is projected to lead the market with anticipated revenues of USD 1.6 billion during the forecast period. Immunoturbidimetric assays stand out for their affordability, especially compared to pricier options like CLIA and ELISA. This cost advantage appeals to a broad spectrum of healthcare providers, notably smaller clinics and budget-constrained laboratories. These assays are celebrated for their swift processing and efficiency.

In 2023, North America accounted for USD 1.2 billion in the C-reactive protein testing market and is poised for significant growth in the coming years. The region grapples with a high prevalence of chronic diseases, notably cardiovascular ailments and diabetes. This uptick drives the demand for CRP testing, as monitoring CRP levels is common for assessing inflammation in these conditions. North America's advanced healthcare infrastructure and broad access to diagnostic technologies further fuel the CRP testing market. The region's embrace of innovative diagnostic tools and a proactive stance on early disease detection amplify CRP test usage.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic disorders such as inflammatory diseases
  - 3.2.1.2 Surge in demand for CRP testing for diagnosis and management of chronic diseases
  - 3.2.1.3 Advances in technology
  - 3.2.1.4 Growing demand for direct-to-home testing services
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of standardization
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Reimbursement scenario
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Kits and reagents

Chapter 6 Market Estimates and Forecast, By Assay Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemiluminescence immunoassay (CLIA)
6.3 Enzyme-linked immunosorbent assay (ELISA)
6.4 Immunoturbidimetric assay
6.5 Other assay types

Chapter 7 Market Estimates and Forecast, By Detection Range, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 High-sensitivity CRP (hs-CRP)
7.3 Standard CRP

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Cardiovascular diseases
8.3 Infectious diseases
8.4 Chronic inflammatory diseases
8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic laboratories
9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa